IHC demonstrated TRAIL-R2 expression in NSCLC patient vasculature and therefore TRAIL-induced collapse of tumor blood vessels was proposed as an alternative or complementary therapeutic strategy (89). The gene discussed is TNFRSF10B; the disease is non-small cell lung carcinoma.